Pfizer (NYSE:PFE) Trading 1.5% Higher Following Analyst Upgrade

Pfizer Inc. (NYSE:PFE)’s stock price traded up 1.5% during trading on Monday after UBS Group raised their price target on the stock from $25.00 to $27.00. UBS Group currently has a neutral rating on the stock. Pfizer traded as high as $27.57 and last traded at $27.3240. 44,069,163 shares were traded during trading, a decline of 2% from the average session volume of 44,758,160 shares. The stock had previously closed at $26.92.

PFE has been the topic of a number of other reports. BMO Capital Markets restated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.24.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer renewed a licensing agreement with Trellus Health to continue using patient‑support educational content for its IBD digital app — supports recurring non‑drug revenue and digital patient engagement efforts. Trellus Health shares jump 39% on Pfizer deal renewal
• Positive Sentiment: Two outlets reported analyst price target uplifts: AmericanBankingNews noted a raise to $28.00 (positive for sentiment), and UBS raised its target to $27 (while keeping a Neutral rating) — these lifts can support the stock despite mixed conviction. Pfizer (PFE) Price Target Raised to $28.00
• Positive Sentiment: Coverage note: Zacks highlighted Pfizer’s outperformance vs. the broader market, reflecting short‑term bullish momentum among investors. Pfizer (PFE) Outperforms Broader Market: What You Need to Know
• Neutral Sentiment: Pfizer Limited corrected a technical XBRL filing error — a procedural fix that removes a potential reporting concern but is unlikely to affect fundamentals. Pfizer Limited Rectifies Technical Error in XBRL Financial Filing
• Neutral Sentiment: Broader sector news (Frontier Medicines appointing an industry veteran) is unlikely to directly affect Pfizer’s stock but can influence sentiment in biotech/pharma names. Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors
• Neutral Sentiment: Comparative coverage (Johnson & Johnson vs. Pfizer) highlights Pfizer’s dividend yield and valuation but offers no new company‑specific catalyst. Better Buy Right Now: Johnson & Johnson Vs. Pfizer
• Negative Sentiment: BofA trimmed its price target to $26 (from $27) and kept a Neutral rating — a downward revision that signals caution on near‑term growth and may cap upside. BofA Lowers its Price Target on Pfizer (PFE) to $26 from $27
• Negative Sentiment: Earlier analyst downgrades drove intraday weakness (reported trading down ~1.2%), reflecting continuing analyst scrutiny and potential short‑term selling pressure. Pfizer (NYSE:PFE) Trading Down 1.2% on Analyst Downgrade

Institutional Trading of Pfizer

A number of large investors have recently modified their holdings of PFE. Vanguard Group Inc. increased its holdings in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the last quarter. State Street Corp increased its holdings in Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after buying an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC increased its holdings in Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the last quarter. Morgan Stanley increased its holdings in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. Finally, Norges Bank purchased a new position in Pfizer in the fourth quarter valued at $1,830,986,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

The firm has a fifty day simple moving average of $27.22 and a 200-day simple moving average of $25.98. The company has a market cap of $155.37 billion, a PE ratio of 20.09 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.63 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.